FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:809-811 March 13, 1997 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Motzer, R. J. PubMed Citation

To the Editor: We would like to add to the excellent review of renal-cell carcinoma by Motzer et al. (Sept. 19 issue)¹ updated information concerning the treatment of patients who have metastatic renal-cell carcinoma with interleukin-2. The authors cite data on 255 patients treated with high-dose bolus infusions of interleukin-2, of whom 14 percent had complete or partial responses for a median duration of 23 months.² The quality of these responses was excellent, with over 60 percent of partial responses involving more than 90 percent regression of all measurable disease. The quality and durability of these responses prompted the Food . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., Mazumdar, M. (2002). Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. JCO 20: 289-296 [Abstract] [Full Text]